Document Detail

Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
MedLine Citation:
PMID:  2180267     Owner:  NLM     Status:  MEDLINE    
A variety of double-blind studies have compared the efficacy of hydroxymethylglutaryl coenzyme A reductase inhibitors (lovastatin and simvastatin) with that of control agents (cholestyramine, fibrates and probucol) in patients with type IIA or IIB primary hypercholesterolemia. Results have shown that both lovastatin and simvastatin are more effective than the standard therapies with regard to reducing total and low-density lipoprotein cholesterol. Decreases in triglycerides and increases in high-density lipoprotein cholesterol were generally greater with fibrates. Ongoing studies are assessing the benefits of lovastatin and simvastatin in reducing the incidence of mortality from coronary artery disease, as well as causing regression of coronary atheroma.
J F Walker; D R Shapiro
Related Documents :
18333357 - Apolipoproteins a-i and b-markers in coronary risk evaluation.
9400857 - Discrimination of metabolite from lipid and macromolecule resonances in cerebral infarc...
17399827 - Current questions regarding the use of statins in patients with coronary heart disease.
7301687 - Myocardial infarction in familial hyper-alpha and hypo-beta-lipoproteinaemia.
23739937 - Five-year outcomes following pci with des versus cabg for unprotected lm coronary lesio...
3119687 - Effect of calcium-binding additives on ventricular fibrillation and repolarization chan...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  65     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1990 Mar 
Date Detail:
Created Date:  1990-04-19     Completed Date:  1990-04-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  19F-22F     Citation Subset:  AIM; IM    
Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bezafibrate / therapeutic use
Cholestyramine Resin / therapeutic use
Double-Blind Method
Gemfibrozil / therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hypercholesterolemia / blood,  drug therapy*
Lipids / blood
Lovastatin / analogs & derivatives,  therapeutic use
Probucol / therapeutic use
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 11041-12-6/Cholestyramine Resin; 23288-49-5/Probucol; 25812-30-0/Gemfibrozil; 41859-67-0/Bezafibrate; 75330-75-5/Lovastatin; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  At what levels of total low- or high-density lipoprotein cholesterol should diet/drug therapy be ini...
Next Document:  Clinical experience with lovastatin.